Drug
Nalmefene
Nalmefene: highest development phase Phase 3, developed by Lundbeck. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nalmefene NCT00811941 | Phase 3 | Alcohol Dependence |
| Nalmefene 18 mg, then placebo NCT01969617 | Phase 1 | Alcohol Dependence |
Latest
No recent events.
Follow Nalmefene on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.